Alina Markova, MD, on the Rationale for Assessing Topical Ruxolitinib in Cutaneous Chronic GVHD

Article

Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

In an interview with CancerNetwork® during the 2022 Tandem Meeting, Alina Markova, MD, dermatologist and director of inpatient consultative dermatology at Memorial Sloan Kettering Cancer Center, discussed the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream (Opselura) in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease (GVHD). She highlights that other topical treatments for the disease, such as steroids, can negatively impact survivors’ quality of life due to adverse effects (AEs) such as bruising and skin thinning. This leaves an unmet need in this patient population.

Transcript:

There are currently no FDA-approved topical therapies for chronic cutaneous [GVHD]. The main topical treatment that is currently used for chronic cutaneous [GVHD] is topical steroids. Topical steroids with long-term use have significant toxicity, [such as] skin thinning and bruising—things that are irreversible and can affect the quality of life of our survivors. Other treatments that are used off label are topical calcineurin inhibitors such as tacrolimus [Protopic], and they have AEs such as burning. Ultimately, both are ineffective and we need other treatments in order to increase [the number of] tools that we have to treat cutaneous involvement of GVHD.

Reference

Markova A, Prockop SE, Dusza S, et al. Interim results of a pilot, prospective, randomized, double-blinded, vehicle-controlled trial on safety and efficacy of a topical inhibitor of Janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease. Presented at: 2022 Transplantation & Cellular Therapy Meetings; Salt Lake City, UT; April 23-26, 2022. Abstract 390.

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content